EXCLUSIVE: The U.K. drugmaker currently has five approved cancer medicines and a clinical-stage portfolio of about 15 assets.
Source link
About The Author
GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree